NEWSIO · ECONOMIC NEWS

EN zh-TW

newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

biotech / news / 2026-06-09 / MarketScreener

Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion.

GSK is acquiring Nuvalent for $10.6 billion to expand its lung cancer treatment portfolio.

KEY POINTS

Nuvalent's share price rose following the acquisition agreement with GSK.
JM Smucker's fourth-quarter profits exceeded Wall Street expectations due to higher product prices.
Vail Resorts lowered its full-year net income guidance, citing challenging weather in the western US.

On this episode of Stock Movers with Alexis Christoforous: - Nuvalent (NUVL) shares are higher on news GSK agreed to buy Nuvalent for $10.6 billion, securing a US biotech firm developing treatments for lung cancer. - JM Smucker (SJM) shares are on the move after it posted fourth-quarter profits that beat Wall Street expectations as higher prices helped boost the packaged food company. - Vail Resorts (MTN) is dropping after the ski resort operator cut its net income guidance for the full year, attributing the reduction to "historically challenging" weather conditions in the western US. The guidance missed the average analyst estimate. Bloomberg videos, provided by MT Newswires

COMPANIES

Read the full story on MarketScreener → →

Summarized by Newsio from MarketScreener. How we summarize →

Meningioma is the most common brain tumor in adults.

Scientists who study the Y chromosome expect to find a record of loss.

A 10-year study in sub-Saharan Africa revealed that a higher dose of the oral medication Hydroxyurea improved survival and growth outcomes in children with sickle cell anemia.